Obesity, Low-Carb Diets and the Atkins Revolution: Healthy Profits from Big Issues in Food and Drinks is among several in-depth reports on consumer marketing trends now offered through FDC Reports. The report contains primary research from an industry opinion survey of over 4,000 senior executives in the global food and drink industry. The 1Datamonitor report is available through FDC Reports by contacting Denise Peterson at 2d.peterson@elsevier.com or 301-664-7143. FDC Reports is offering a number of Datamonitor reports spanning the prescription and OTC drug industries as well as focused consumer marketing studies...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
